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SUMMARY 
Phospholamban (PLN) is a small sarcoplasmic reticulum (SR) protein that in the 
dephosphorylated state tonically inhibits the SR Ca2+-ATPase (SERCA2a). Different 
type of evidence to be described, points to PLN as a crucial regulator of basal cardiac 
Ca2+ cycling, contractility and relaxation and as a main determinant of β -adrenergic 
stimulatory responses in vivo. The involvement of PLN and PLN phosphorylation under 
pathological conditions will be also discussed. 
 
INTRODUCTION 
The central players of excitation-contraction-coupling (ECC) 
Excitation-contraction-coupling can be defined as the series of events beginning at the 
level of the sarcolemma by membrane depolarization, and finishing at the level of the 
sarcomeres with the interaction and sliding of myofilaments to produce contraction. 
Ca2+ ions are responsible for the coupling between both events. Figure 1 is a schematic  
 
 
 
Figure 1: The different steps of ECC in the heart are depicted in black. In violet and blue: 
cAMP/PKA/CaMKII cascades triggered by β-adrenoceptor stimulation.  
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illustration of this mechanism. Upon depolarization, Ca2+ enters the cell through the 
voltage-dependent L-type Ca2+ channels (Dihydropyridine receptors, DHPRs) and 
triggers Ca2+ release from the sarcoplasmic reticulum (SR) through the activation of the 
SR Ca2+ channels or ryanodine receptors (RyR2). This process, known as Ca2+-induced-
Ca2+-release1, amplifies and coordinates the Ca2+ signal.  Ca2+ then binds to the 
myofilaments allowing their interaction. The decrease in cytosolic Ca2+ triggers 
relaxation. This decrease is mainly induced by the SR Ca2+-ATPase (SERCA2a), which 
mediates Ca2+ uptake into the SR, and, to a lesser extent, by the Na+/Ca2+ exchanger 
(NCX), which transfers Ca2+ to the extracellular space2. By mediating SR Ca2+ uptake, 
the activity of SERCA2a also influences cardiac contractility since it determines the 
size of the luminal Ca2+ store that is available for release in the next beat. The activity of 
SERCA2a, which in humans determines the rate of removal of >70% of cytosolic Ca2+, 
is under the control of a closely associated SR protein named phospholamban (PLN), 
the endogenous inhibitor of SERCA2a3. In this review we will focus on PLN and its 
role in the regulation of cardiac function under physiological and pathological 
conditions.   
 
PLN	  structure	  and	  interaction	  with	  the	  SR Ca2+-ATPase	  	  
PLN is a small protein spanning the SR membranes, expressed almost exclusively in 
cardiac, smooth and slow- twitch skeletal muscles. The cloning of PLN revealed that it 
is a 52-aminoacid protein of 6.1 kDa that forms a homopentamer, which accounts for 
the original observation that phosphorylated PLN has an apparent mass of 22 kDa4. 
From analysis of the amino-acid sequence, it was suggested that the protein is organized 
in three domains: cytosolic domain Ia [amino acids (AA) 1–20] containing serine (Ser) 
16, the PKA phosphorylation site, and threonine (Thr) 17, the CaMKII phosphorylation 
site; cytosolic domain Ib (AA 21–30) and domain II (AA 31–52), which traverses the 
membrane5.  
It has been proposed that a physical protein-protein interaction between the cytoplasmic 
domain of PLN (AA 2-18 of each subunit) and SR Ca2+-ATPase (AA 336-412 and 467-
762) is critically involved in the inhibitory effect of PLN on the Ca2+-pump. However, 
the interaction of this PLN domain with the SERCA2a appears to be insufficient per se 
to alter the apparent Ca2+ affinity of SERCA2a. Moreover, coexpression of the 
hydrophobic membrane spanning PLN domain with SERCA2a has revealed that this 
PLN domain was able to modify the Ca2+ affinity of the pump suggesting that both 
domains are involved in the inhibitory effect of PLN on SR Ca2+-ATPase5.  
In in vitro expression systems, PLN monomer appears to be the more effective Ca2+-
pump inhibitor. Moreover, gain of function experiments demonstrated that 
overexpression of two PLN monomeric mutants (L37A and I40A) in transgenic mouse 
models are superinhibitors of SERCA2a. This type of evidence indicates that PLN 
exists in the SR as an inactive pentamer (storage form), which depolymerizes into 
functional monomers prior to interaction with SERCA2a5. Of interest, overexpression 
of HAX-1, a ubiquitously expressed anti-apoptotic protein, reduced SERCA2a activity 
in isolated cardiomyocytes and in vivo, leading to depressed myocyte Ca2+ kinetics and 
mechanics. Mechanistically, HAX-1 promotes the formation of PLN monomers6. 
 
PLN Function 
Being PLN an endogenous inhibitor of the SR Ca2+-pump, there are two main 
mechanisms by which it may regulate cardiac relaxation and contractility (Figure 2):   
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1. Alterations in the relationship PLN/SERCA2a, which would either increase or 
decrease the number of SERCA2as inhibited by PLN. 
2. Modifications of the phosphorylation status of PLN, owing to the fact that PLN 
phosphorylation relieves PLN inhibition on the pump.  
 
1. Relationship PLN/SERCA2a 
The use of gene knockout and transgenic mouse models, in which the expression levels 
of PLN has been ablated, reduced or increased, constituted a crucial step in the 
recognition of PLN as an endogenous inhibitor of SERCA2a7,8. Ablation of PLN 
enhanced contractility and relaxation. This hypercontractile function of PLN-deficient 
hearts (PLN-/-) was associated with increases in the apparent affinity of SERCA2a for 
Ca2+ and in the intraluminal SR Ca2+ content7. Opposite effects were observed with the 
overexpression of PLN8 (Figure 2Aa-b).  
 
 
Figure 2: A. Different ways of modifying the inhibitory effect of PLN on SERCA2a B. Regulation of the 
phosphorylation state of PLN and its functional consequences.  
 
2. PLN phosphorylation pathways 
In vitro experiments demonstrated that phosphorylation of PLN at Ser16 site by PKA 
and at Thr17 site, by CaMKII reverses PLN inhibitory function, probably through 
conformational changes that disrupt PLN/ SERCA2a interactions5 with the consequent 
increase in SR Ca2+ uptake (Figure 2Ac and 2B). In vitro studies also indicate that PKA 
and CaMKII phosphorylations are independent of each other and when acting together 
they are additive. A crucial determinant of the status of phosphorylation of PLN, which 
is frequently overlooked, is the activity of the type 1 phosphatase (PP1), the major SR 
phosphatase that specifically dephosphorylates PLN9, in turn under the control of 
different kinases and phosphatases (See for review Mattiazzi et al., 2005)10.  
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PLN and β-adrenergic stimulation 
Cardiac function is regulated on a beat-to-beat basis through the sympathetic nervous 
system. Sympathetic stimulation of cardiac β-adrenergic receptors (β-AR) induces 
positive chronotropic (heart beats more frequently), inotropic (heart beats stronger), and 
lusitropic (heart relaxes faster) effects, -the so-called “fight or flight response”-, the 
most effective mechanism to acutely increase output of the heart. Activation of β-AR by 
β1- agonists at the cell membrane, initiates a signal-transduction pathway (Figure 1) that 
proceeds through Gs protein to stimulate cyclic AMP formation by adenylate cyclase 
and PKA activation, which then phosphorylates and alters the function of several 
cardiac proteins among which PLN is predominant in determining the mechanical 
effects of β -agonists. Two different experimental approaches eloquently support this 
contention: 1. Dialysis of ventricular myocytes with a monoclonal antibody against 
PLN, virtually suppressed the mechanical effects of the β-agonists11; 2. Studies in 
different cardiac preparations from PLN-deficient mice indicated a significant 
attenuation of the inotropic and lusitropic effects of isoproterenol, compared with wild 
type preparations7.  
Wegener et al.12 first demonstrated that there were only two sites of PLN 
phosphorylated during β-AR stimulation: Ser16 (PKA site) and Thr17 (CaMKII site).  
Moreover, phosphorylation at Ser16 precedes that at Thr17, although at steady state, both 
sites were phosphorylated in approximately equimolar amounts. Phosphorylation of 
PLN by increasing SR Ca2+ uptake, increases SR Ca2+ refilling in each beat and 
therefore enhanced relaxation and contractility (Figure 2B). Recent data demonstrate 
that it is the β 1-AR subtype that mediates CaMKII activation and PLN Thr17 
phosphorylation in response to isoproterenol infusion13.  
Isoproterenol-induced phosphorylation of PLN by PKA and CaMKII activation was 
also observed by using different techniques which corroborate that dual phosphorylation 
of PLN does occur ex vivo as it was the case of the in vitro experiments14-17.  
 
Interdependence of PLN phosphorylation pathways during β-adrenergic stimulation.  
Earlier attempts to phosphorylate PLN by CaMKII in the intact heart had systematically 
failed unless cAMP levels within the cell increase14,15,18. These findings suggested an 
interaction between PLN phosphorylation pathways. Experiments in transgenic mice, 
expressing either PLN-wild type (PLN-WT), or the Ser16→Ala mutant PLN, 
demonstrated that the phosphorylation of Ser16 of PLN is a prerequisite for the 
phosphorylation of Thr17 19, in line with earlier findings which indicated the dependence 
of the phosphorylation of Thr17 on intracellular cAMP levels15. Experiments in 
Thr17→Ala mutant PLN hearts further showed that Ser16 can be phosphorylated 
independently of Thr17 in vivo and that phosphorylation of Ser16 was sufficient for 
mediating the maximal cardiac responses to β-adrenergic stimulation20. These 
experiments suggested a predominant role of the phosphorylation of Ser16 over that of 
Thr17, in the mechanical effect produced by β-adrenergic stimulation. The combination 
of phosphorylation site-specific antibodies with quantification of 32P incorporation into 
PLN further helped to clarify the relative role of Ser16 and Thr17 phosphorylations16,17. 
Lowering extracellular Ca2+ significantly decreased total PLN phosphorylation and the 
shortening of half relaxation time induced by the β-agonist isoproterenol (Figure 3A). 
Figure 3B shows that the decrease in total PLN phosphorylation was exclusively 
produced by the decrease in CaMKII-dependent Thr17 site phosphorylation. These 
experiments indicated that phosphorylation of Thr17 accounted for approximately 50% 
of the total PLN phosphorylation and rate of relaxation, at the highest isoproterenol 
concentrations (≥10 nM). However similar type of experiments demonstrated that there 
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was no contribution of the CaMKII pathways to the total PLN phosphorylation at the 
lowest isoproterenol concentrations17. This finding may be attributed to the modest 
increase in PKA activity produced by the low β-adrenergic stimulation, which would 
produce only a small increase in intracellular Ca2+, not enough to activate CaMKII and 
phosphorylate Thr17 site (See Figure 1). Since it has been shown that PKA inhibits PP1 
(See for references10), the modest increase in PKA activity would also fail to 
significantly inhibit the phosphatase that dephosphorylates PLN, further favoring the 
dephosphorylated state of Thr17 residue. These results may explain the failure to find 
PLN phosphorylation in transgenic mice in which Ser16 site was mutated to Ala, i.e., the 
lack of phosphorylation of the Ser16 site precludes the increase in intracellular Ca2+ 
necessary to phosphorylate Thr17,19.  
 
 
 
Figure 3. Phosphorylation of Ser16 and Thr17 of PLN similarly contribute to the relaxant effect of 
maximal β-AR stimulation. 
 
Taken together, these findings demonstrated the additive nature of PKA and CaMKII 
pathways of PLN phosphorylation, in agreement with the in vitro results5. In addition, 
they indicated that both PLN phosphorylation sites equally contribute to the total PLN 
phosphorylation at the highest levels of β-adrenergic stimulation16. Finally, that 
CaMKII is a β -AR mediator being PKA its upstream activator, through the PKA-
dependent increases in Ca2+. 
Interestingly, β-AR may activate Epac, a guanine nucleotide exchange protein directly 
activated by cAMP, independently of PKA. Activation of Epac has been recently 
associated with an increase in CaMKII activity and phosphoryltion of Thr17 of PLN. 
The mechanism of this activation remains unclear (See for references21).  
Finally, it is important to mention that cGMP-dependent protein kinase and Akt, 
phosphorylate PLN at Ser16 and Thr17 residues, respectively, with the consequent 
increase in SR Ca2+ handling and contractility10,22.  
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PLN under pathological conditions 
There are several pathological situations in which PLN and PLN phosphorylation are 
involved. Among them ischemia/reperfusion and heart failure are particularly relevant. 
Interestingly, phosphorylation of PLN and the consequent increase in SR Ca2+ uptake, 
results beneficial for heart performance in some cases, whereas it is detrimental in 
others. Obviously, in all situations the effects of PLN phosphorylation is the same, i.e. 
to increase SR Ca2+ refilling. As will be discussed below, dissimilar outcomes of the 
same effect (increase in SR Ca2+ uptake) may arise from differences in the extent or 
type of Ca2+ handling alterations, which may be summarized in at least two mutually 
non exclusive reasons: 1. The different level of SR Ca2+ uptake and load produced by 
PLN phosphorylation; 2. The status/activity of other proteins, which share with PLN the 
task of intracellular Ca2+handling, like the RyR2 and the NCX.  
 
Ischemia/reperfusion injury (I/R)  
In the last few years, our laboratory has described a dual effect of CaMKII-dependent 
phosphorylations in I/R, which may be attributed to a CaMKII-dependent 
phosphorylation of PLN at the Thr17 site: 1. A beneficial effect in the reversible I/R also 
known as stunned heart. This effect consists in an enhancement of the contractile and 
intracellular Ca2+ transient recovery. Direct measurements of intracellular Ca2+ and 
transgenic mice in which Thr17 site of PLN and/or Ser16 site of PLN were mutated to 
Ala, demonstrated that the phosphorylation of Thr17 residue of  PLN, that occurs at the 
onset of reperfusion was essential for the mechanical and intracellular Ca2+ handling 
recovery observed23,24 2. A detrimental effect (apoptosis and necrosis), involving 
CaMKII-activation, Thr17 phosphorylation of PLN and mitochondrial alterations, in the 
irreversible I/R.  These effects appear to be associated with a degradation of RyR2 and a 
increase in SR Ca2+ release25,26. Similar opposite results of PLN phosphorylation and 
increase in SR Ca2+ uptake on myocardial performance, have been obtained by others. 
For instance, in PLN-/- mice, the absence of PLN exacerbates I/R injury27. Similarly, 
the protective effect (decreased number of apoptotic cells) of chronic CaMKII inhibition 
in transgenic mice expressing a CaMKII inhibitory peptide (AC3-I mice) and submitted 
to myocardial infarction, was absent in interbred AC3-I mice with PLN-/- mice28. In 
these animals, the absence of the inhibitory effect of PLN greatly enhances SR Ca2+ 
uptake and load. In contrast, other results associate the increase in PLN phosphorylation 
observed after the inducible expression of inhibitor-1, -a PLN phosphatase inhibitor-, 
with the beneficial effect of this inhibitor in I/R injury29. Figure 4 offers an 
interpretation to these apparently contradictory results: Phosphorylation of PLN would 
be beneficial, favoring SR Ca2+ handling, provided that SR Ca2+ uptake and load are 
moderate (or even high), and no other alterations occurred at the level of SR. This 
would be the case of the beneficial effect observed in the reversible I/R24 (Figure 4A). 
In a similar way, the increase in SR Ca2+ uptake due to the absence of PLN that occurs 
in PLN-/- mice, produces a very significant improvement of basal contractility (Figure 
4B), which is tolerated throughout the life of the animal without deleterious 
consequences if left “unstressed”. In contrast, high or even moderate increases in SR 
Ca2+ content in hearts submitted to stress with alterations of RyR2s (degradation, 
phosphorylation, redox changes), may evolve to a detrimental effect due to an increase 
in Ca2+ release/leak that favors mitochondrial damage. This would be the case of our 
experiments of irreversible I/R25,26 (Figure 4C) and might be also the case of PLN-/- 
mice submitted to I/R27.  
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Heart Failure 
Most findings now indicate that the levels of PLN protein remain unchanged, whereas 
the levels of SERCA2a protein decrease in human heart failure, altering the functional 
PLN/SERCA2a ratio and resulting in higher inhibition of the Ca2+ pump (Figure 2Ad). 
PLN is also less phosphorylated in heart failure, becoming more inhibitory overall. As a 
consequence, SERCA2a decreases the amount of Ca2+ reuptake by the SR, lowering SR 
Ca2+ refilling, relaxation and contractility30. In most heart failure models, there is also 
an increase in NCX expression, which would compensate for the decrease in SERCA2a 
and the consequent impaired relaxation, although at the enormous cost of a loss of 
intracellular Ca2+, which is extruded from the cell by the exchanger (See Figure 1)30. 
Together, these alterations are main determinants of the decrease in contractility of 
failing hearts. The observed reduction in the Ca2+ available for myofilament activation 
and reduced SR Ca2+ reuptake are obvious targets to improve myocyte contraction and 
relaxation and, thus, cardiac pump function. Potential therapeutic strategies are to 
increase SERCA2a levels or to attenuate the PLN inhibitory effect on SERCA2a.  
 
 
Figure 4: Dual role of PLN phosphorylation and increased SR Ca2+ uptake on cardiac function. 
 
However, whereas some studies have clearly shown the beneficial effects of improved 
SR Ca2+ cycling through PLN ablation on cardiac function and remodelling, others have 
shown that normalization of myocyte Ca2+ handling might not translate into improved 
cardiac function in vivo or into reversal of remodelling. Just to mention a few results, 
overexpression of SERCA2a, using recombinant adenovirus-mediated gene transfer, led 
to enhanced contractility in isolated myocytes31 and improved cardiac function, 
metabolism and survival in a rat aortic constriction model of heart failure32. These 
studies support the idea that an enhanced expression of SERCA2a restores disturbed 
intracellular Ca2+ handling by decreasing the relative ratio of PLN/SERCA2a. 
Interestingly, these results have led to the ongoing clinical trials in patients with 
established heart failure which recently reported promising results33. In contrast, in mice 
that overexpress both a G protein, Gαq, involved in α-adrenergic and angiotensin II 
signallings, and a mutant myosin binding protein C that causes familial hypertrophic 
cardiomyopathy in humans, PLN ablation was less successful: cardiac myocyte 
contractility was rescued, but no improvement was observed in whole-heart contractile 
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function or in cardiac dilation34. A recent study by Zhang et. al35 confirms the 
dichotomy between the rescue of global Ca2+ handling by PLN-/- mice and the 
impairment of the heart failure phenotype. Overexpression of CaMKIIδC in mice 
produced dilated cardiomyopathy which was not rescued by the crossbreed with PLN-/-, 
but rather exacerbated. In exploring the possible mechanisms of this therapeutic failure, 
the authors show that SR Ca2+ release and uptake were normalized. However, the SR 
Ca2+ content was supranormal and RyR2s were phosphorylated. The authors postulated 
that these changes may be the cause of the observed increase in SR Ca2+ leak through 
the phosphorylated RyR2s which in turn produces mitochondrial Ca2+ overload and 
apoptosis and thus exacerbates heart failure (This possibility is schematized in Figure 
4D). 
 
In summary, PLN plays a major role in the regulation of cardiac relaxation and 
contractility, being the main effector of the β-adrenergic cascade at the cellular level. 
PLN has also a significant role in different heart diseases and several studies point to 
this protein as a potential target to increase SR Ca2+ uptake. However, it is important to 
define how and in which conditions this increase may be useful.  
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